ARTICLE | Company News
Hyal other research news
January 10, 1994 8:00 AM UTC
The new study will assess the effectiveness of the drug in resolving basal cell carcinomas beyond the 8-week treatment tested in the company's on-going Phase III trials in Australia and Canada. The new study will compare recurrence rates folowing treatment with HYAL-CT1101 with recurrence rates following currently used invasive therapy.
According to HYALF, the FDA and the company concluded that the current Phase III U.S. study was likely to produce results similar to those seen in Australia and Canada, making it unnecessary to continue the total planned recruitment of 200 patients. The agency will accept the international studies for regulatory filing. ...